{"filings":[{"id":1315158,"accession_number":"0001171843-26-004333","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-06-29T11:06:42+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"BioCryst shuts internal discovery, closes Birmingham facility; navenibart Phase 3 enrollment complete; guidance improved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.","Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line data expected Q3 2027.","Resolved manufacturing delay for ORLADEYO oral pellets; product available early August 2026.","2026 non-GAAP operating expense guidance lowered to $420-440M from $450-470M; revenue guidance reaffirmed at $635-660M.","BCX17725 (Netherton syndrome) Phase 1 Part 4 dosing ongoing; proof-of-concept data expected year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027482,"accession_number":"0001171843-26-004096","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-06-12T20:10:10+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioCryst shareholders approve 7M share increase to Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Incentive Plan approved with 119.8M for, 63.3M against, adding 7M shares to the Plan.","Directors Heggie, McKee, Stonehouse re-elected; each received >170M votes for.","Non-binding say-on-pay passed but 56.8M (31% of votes cast) voted against.","Ernst & Young ratified as 2026 auditor with 210.3M votes for, 7.2M against.","34.0M broker non-votes recorded on director elections, say-on-pay, and plan vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99401,"accession_number":"0001171843-26-003052","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q1 ORLADEYO rev $148.3M (+11% YoY); non-GAAP op profit $54.2M; licenses EU navenibart rights for $70M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.","Non-GAAP operating profit of $54.2M; guidance reaffirmed: FY2026 ORLADEYO rev $625-645M, total rev $635-660M, op ex $450-470M.","Licensed European navenibart rights to Neopharmed Gentili for $70M upfront, up to $275M milestones, plus 18-30% royalties.","Navenibart pivotal study ALPHA-ORBIT enrollment on track to complete by June 2026; US regulatory filing targeted by end 2027.","Appointed Sandeep Menon as Chief R&D Officer in April; ended avoralstat DME program to focus on rare diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":156413000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99400,"accession_number":"0001171843-26-002960","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.","Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.","Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.","Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115380,"accession_number":"0001171843-26-001119","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.","Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).","ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.","Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.","Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":874837000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115379,"accession_number":"0001140361-26-002200","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.","Adds navenibart (Phase 3 plasma kallikrein inhibitor) offering every-3/6-month HAE dosing.","Astria CEO Jill Milne joins BioCryst board; John Ruesch becomes Chief Technical Operations Officer.","BioCryst obtained $400M term loan from Blackstone funds (5-yr, SOFR+4.5% with PIK option).","Astria's nine-month 2025 net loss $98.4M; had $227.7M cash/investments at Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115376,"accession_number":"0001171843-26-000405","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K/A","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.","Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.","On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115378,"accession_number":"0001171843-26-000213","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.","Q4 2025 ORLADEYO net revenue $151M (+22% YoY; +36% comparable basis excl European revenue).","Cash, cash equivalents, restricted cash & investments at Dec 31, 2025: $338M.","FY2026 guidance: ORLADEYO rev $625-645M; total rev $635-660M; non-GAAP op ex $380-390M (excl Astria).","Expected close of Astria Therapeutics acquisition in Q1 2026; adds $70-80M non-GAAP op ex for navenibart Phase 3 and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":874837000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115377,"accession_number":"0001171843-26-000154","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.","The price increase applies to both the 150mg and 110mg capsule strengths.","BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131787,"accession_number":"0001171843-25-007909","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst gets FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ORLADEYO oral pellet formulation for prophylactic therapy in HAE children aged 2 to <12 years.","First and only oral prophylactic treatment for this age group; previously only injectable options were available.","Approval supported by APeX-P trial interim data showing early and sustained attack rate reductions with no new safety signals.","BioCryst plans EU, Japan, and other regulatory filings; ORLADEYO capsule already approved for ages 12+ since Dec 2020.","More than 3,500 patients in the US have been prescribed ORLADEYO to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131786,"accession_number":"0001171843-25-007878","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst board chair Nancy Hutson to retire; Vincent Milano named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nancy J. Hutson notified retirement from BioCryst board, effective earlier of Astria acquisition close or 2026 annual meeting.","Hutson to continue as Chair and committee member until Retirement Date; cited no disagreement with board or management.","Vincent J. Milano elected as next Board Chair, effective on Hutson's Retirement Date.","Hutson served 14 years on the BioCryst board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131785,"accession_number":"0001140361-25-044110","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.","BioCryst expects the merger with Astria Therapeutics to close in Q1 2026.","Remaining conditions still required; deal previously announced.","Removal of antitrust risk is a positive step toward closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131784,"accession_number":"0001171843-25-006881","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).","Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).","FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.","Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.","Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":468282000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131783,"accession_number":"0001140361-25-038031","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","5.02","8.01","9.01"],"status":"ready","headline":"BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.","Blackstone provides $550M senior secured credit facility ($350M term loan + $50M committed delayed draw + $150M uncommitted) to fund deal.","Q3 2025: ORLADEYO demand strong with no impact from new competition (no specific figures given).","Astria CEO Jill Milne appointed to BioCryst board effective at merger close; receives $500K equity grant.","BioCryst paid off and terminated April 2023 loan agreement with BioPharma Credit PLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131782,"accession_number":"0001140361-25-036875","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BioCryst completes sale of European ORLADEYO business; receives $250M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.","Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).","Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.","Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.","European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148383,"accession_number":"0001171843-25-005265","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.","Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.","Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.","No disagreement cited with Board or management regarding company operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148382,"accession_number":"0001171843-25-004977","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).","Operating income $29.8M (up from $8.8M); non-GAAP op income $57.0M (up from $21.9M).","Net income $5.1M ($0.02 EPS) vs net loss $12.7M ($0.06 loss) in Q2 2024.","Made additional $50M term debt paydown in July; plans to retire remaining $199M with proceeds from European ORLADEYO sale expected to close early Oct.","Full-year 2025 ORLADEYO revenue guidance maintained at $580M-$600M; pipeline on track for data in two programs by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":308887000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148381,"accession_number":"0001171843-25-004869","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.","Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.","Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.","Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.","Stonehouse cited no disagreement; transition follows succession planning process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148380,"accession_number":"0001171843-25-004324","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioCryst appoints Babar Ghias as CFO and Head of Corporate Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.","Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.","Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.","Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.","CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167167,"accession_number":"0001140361-25-024089","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.","Transaction expected to close in October 2025, subject to antitrust clearance and customary closing conditions.","BioCryst will continue as exclusive supplier of ORLADEYO under a supply agreement and enter IP license, brand support, and transition services agreements.","Sale includes all equity of BioCryst Ireland Limited, which holds European ORLADEYO assets and rights.","The amended IP license may extend to the pediatric line extension of ORLADEYO subject to regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167166,"accession_number":"0001171843-25-004186","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.","Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.","BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.","Sale includes European team; BioCryst saves at least $50M in annual operating expenses.","European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167165,"accession_number":"0001171843-25-004091","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA extends PDUFA goal date for BioCryst's ORLADEYO pediatric NDA to Dec 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA determined submission of additional final reports and formulation data is a major amendment, extending review by three months.","New PDUFA target action date set for December 12, 2025, after original goal date extended.","NDA seeks approval of once-daily ORLADEYO oral granules for HAE in pediatric patients aged 2 to 11 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167164,"accession_number":"0001171843-25-003910","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.","Shareholders approved amended Stock Incentive Plan, increasing shares available by 11,000,000 to 81,090,000 total.","Advisory say-on-pay passed with 143.1M for vs 6.4M against; auditor Ernst & Young ratified with 174.7M for.","Director nominees Steven Galson and Alan Levin re-elected with ~146M votes each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167163,"accession_number":"0001171843-25-003662","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.","Mr. Doyle provides transition services related to CFO succession at $450/hour; all other terms unchanged.","Original agreement effective April 9, 2025; extension announced on May 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167162,"accession_number":"0001171843-25-003152","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts NDA for ORLADEYO granules in HAE ages 2-11; priority review, PDUFA Sep 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for once-daily ORLADEYO oral granules for HAE patients aged 2-11; priority review granted with PDUFA target Sep 12, 2025.","If approved, ORLADEYO would be first targeted oral prophylactic therapy for HAE under age 12.","NDA based on positive interim APeX-P trial data showing well-tolerated, consistent safety, and reduced monthly attack rates.","BioCryst also filed line extension with EMA; regulatory filings planned in Japan and Canada.","ORLADEYO already approved in US for patients 12+ and commercially available in over 30 countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167161,"accession_number":"0001171843-25-002739","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q1 ORLADEYO revenue $134.2M (+51% YoY); raises FY guidance to $580-600M; expects FY 2025 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.","FY 2025 ORLADEYO rev guidance raised to $580-600M (from $535-550M); company expects net income and positive cash flow for full year.","Paid down $75M of Pharmakon debt in April; expects ~$23.5M interest savings over life of loan.","NDA submitted for ORLADEYO oral granules for HAE children aged 2-11; IND cleared for BCX17725 for Netherton syndrome.","% paid ORLADEYO patients increased to ~84% (from 73.5% end 2024); U.S. preference for oral prophylaxis rose to 70%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":145534000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167160,"accession_number":"0001171843-25-002669","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioCryst appoints Steve Frank to board; board size increased to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Frank elected to board effective May 2, 2025, filling new seat after board expansion from 10 to 11 directors.","Frank is chairman of global healthcare investment banking at J.P. Morgan; previously at Bear Stearns.","Initial equity grant of $500,000 (60% options, 40% RSUs), prorated from effective date to 2025 annual meeting.","Frank brings healthcare M&A and capital allocation expertise as BioCryst approaches profitability.","Frank's term expires at 2027 annual meeting; no committee assignments initially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167159,"accession_number":"0001171843-25-002147","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.","CEO Jon P. Stonehouse appointed Interim CFO and Interim Principal Accounting Officer effective April 9.","Company hired former public biotech CFO as financial consultant to support Stonehouse during CFO search.","No change to Stonehouse's compensation arrangements resulting from the interim appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184530,"accession_number":"0001171843-25-001383","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioCryst files patent infringement lawsuit against Annora Pharma over generic ORLADEYO","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Annora Pharma sought FDA approval for generic ORLADEYO, challenging three patents expiring in 2039.","BioCryst filed suit March 10, 2025, in Delaware District Court against Annora, Hetero Labs, Hetero USA, and Camber.","Lawsuit seeks to enjoin generic launch and order FDA approval only after 2039 patent expiry (including extensions).","Six other ORLADEYO Orange Book patents expiring in 2035 were not challenged by Annora.","Company intends to vigorously enforce intellectual property rights protecting ORLADEYO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184529,"accession_number":"0001171843-25-001231","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst CFO Anthony Doyle to resign effective April 9, 2025; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Doyle notified resignation as CFO effective April 9, 2025.","Resignation is not due to any disagreement with the company.","Company has initiated a search for a new CFO; Doyle will remain to assist transition.","Doyle joined in April 2020, helped launch ORLADEYO and strengthen financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184528,"accession_number":"0001171843-25-001020","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).","FY 2024 GAAP operating loss $2.5M; non-GAAP operating profit $62.9M (excl. stock-based comp).","FY 2025 ORLADEYO revenue guidance raised to $535-550M from $515-535M; expects positive EPS in 2H 2025.","Annora Pharma filed ANDA for generic ORLADEYO; company intends to vigorously defend three patents expiring 2039.","NDA submission in 2025 for pediatric ORLADEYO granule (ages 2-11); initial data from BCX17725 and avoralstat expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":450712000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184527,"accession_number":"0001171843-25-000190","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioCryst to present at J.P. Morgan Healthcare Conference on Jan 14; slides posted Jan 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presentation at 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Jan 14 at 6:00 p.m. ET.","Slides covering drug discovery and development programs posted Jan 13 on BioCryst IR website.","No new financial or business updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184526,"accession_number":"0001171843-25-000155","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).","Total FY2024 revenue $450M (+36% YoY); FY2025 total revenue guidance $540-560M.","Expects to approach quarterly EPS profitability and positive cash flow in 2H 2025; targets full-year EPS profitability and positive cash flow in 2026.","Plans 2025 NDA for ORLADEYO granules for children <12; two new pipeline programs to enter clinic (BCX17725, avoralstat).","2025 GAAP op ex guidance $485-495M (incl. ~$60M stock comp); non-GAAP op ex $425-435M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":450712000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184525,"accession_number":"0001171843-25-000112","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioCryst raises ORLADEYO WAC 5% to $44,484.33 per 28-day pack effective Jan 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORLADEYO WAC raised from $42,366.03 to $44,484.33 per 28-day pack (150mg or 110mg).","Price increase of approximately 5% effective January 8, 2025.","The WAC increase applies to both the 150mg and 110mg capsule packs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201106,"accession_number":"0001171843-24-005975","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.","GAAP operating profit of $7.7M vs. loss of $11.9M in Q3 2023; non-GAAP op. profit $24.9M.","Net loss narrowed to $14.0M ($0.07 per share) from $36.1M ($0.19) a year ago.","FY 2024 ORLADEYO revenue guidance raised to $430-435M (top end of prior range); total revenue $443-448M.","Pipeline: BCX17725 for Netherton syndrome entered clinic; avoralstat for DME on track for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":319178000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201105,"accession_number":"0001171843-24-005439","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.","Trial to evaluate safety, tolerability, PK and immunogenicity in healthy adults and Netherton patients.","Initial data from the trial expected by end of 2025; no approved treatments currently exist for the disease.","BCX17725 is BioCryst's first protein therapeutic to advance to the clinic.","Netherton syndrome is an ultra-rare, life-threatening genetic disorder affecting skin, hair, and immune system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217124,"accession_number":"0001171843-24-005393","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.","First ordering period executed at $13.9M for 19,125 doses to be supplied by Sept 2025.","Awarded by HHS ASPR; four optional 12-month ordering periods remain.","Prior CDC contract of $34.7M for up to 50,000 doses concluded in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217123,"accession_number":"0001171843-24-004422","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.","Net loss narrowed to $12.7M ($0.06/share) from $75.3M ($0.40/share); non-GAAP operating profit $21.9M.","ORLADEYO FY2024 revenue guidance raised to $420-435M from $390-400M, citing strong demand and payer improvements.","Discontinuing oral Factor D inhibitor BCX10013 due to insufficient activity; advancing BCX17725 for Netherton syndrome to clinic by end-2024.","Cash $338.1M vs $415.7M a year ago; operating cash use was only $0.2M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":202093000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236894,"accession_number":"0001171843-24-003430","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioCryst shareholders approve 7M-share increase to Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.","Directors re-elected: Nancy J. Hutson, Vincent J. Milano, A. Machelle Sanders; broker non-votes 26,962,524.","Ernst & Young ratified as FY 2024 auditor (167,496,029 for); advisory exec-comp resolution passed (138,402,008 for).","Incentive Plan Proposal passed with 101,846,368 for, 43,055,807 against; plan now includes 12-month minimum vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236893,"accession_number":"0001171843-24-002550","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.","ORLADEYO net revenue grew 30% YoY to $88.9M; full-year guidance raised to $390-$400M (top end of prior range).","Pipeline: BCX17725 (Netherton syndrome) enters clinic by end 2024; avoralstat (DME) trial planned for 2025.","Pediatric HAE trial (APeX-P) enrollment complete; filing for label expansion to children age 2+ expected in 2025.","Cash and investments $338.4M at Mar 31; net cash use Q1 $52.4M, expects ending 2024 cash above $300M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":92761000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254496,"accession_number":"0001171843-24-000967","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).","2024 guidance: ORLADEYO revenue $380-$400M; expects operating profit in 2024, positive EPS and cash flow in 2H 2025.","GAAP net loss Q4 $61.7M ($0.31), FY2023 $226.5M ($1.18); non-GAAP net loss Q4 $56.4M ($0.28).","R&D expenses fell to $70.1M Q4 (-4% yoy); SG&A rose to $64.4M Q4 (+28% yoy) on commercial expansion.","Cash $390.8M at Dec 31, 2023; net cash use $8.6M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":331412000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254495,"accession_number":"0001171843-24-000297","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.","Revisions to stockholder nomination procedures to comply with universal proxy card rules (Rule 14a-19).","Limits stockholder nominee count to number of directors to be elected; clarifies timing for substitute nominations.","Requires soliciting stockholders to use a proxy card color other than white.","Technical and administrative changes also adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254494,"accession_number":"0001171843-24-000112","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst announces FY2023 ORLADEYO revenue $325M (+29%), 2024 guidance $380-400M, sees operating profit in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).","2024 ORLADEYO revenue guidance $380-400M; company reaffirms peak sales target of $1B.","2024 operating expenses expected flat at $365-375M; R&D reduced $20M vs 2023.","Restructuring reduces workforce by 59 jobs (10%); plans to out-license BCX10013 if data supports.","ORLADEYO WAC increased ~5% to $42,366 per 28-day pack, effective January 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":331412000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271971,"accession_number":"0001171843-23-007377","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst director Kenneth B. Lee, Jr. to retire from Board on Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee notified company Nov 28, 2023 of retirement effective Dec 31, 2023.","He served as Audit Committee Chair and Finance Committee member.","Lee cited no disagreement with Board or management regarding company operations.","Lee had been a Board member for 12 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271970,"accession_number":"0001171843-23-007357","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioCryst updates ORLADEYO Japan commercialization; new royalty tier at 80% above threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BioCryst Japan K.K. now handles all commercial promotion for ORLADEYO in Japan; Torii to conduct HAE disease awareness.","Royalty amended: 20% on annual Japanese sales below a prespecified threshold, 80% on sales above that threshold.","BioCryst assumes direct commercial activities for ORLADEYO in Japan via its subsidiary under updated Torii agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271969,"accession_number":"0001171843-23-006717","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst pipeline update: five programs to enter clinic by 2025, R&D spend guided $230-240M in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BCX17725 (fusion protein KLK5 inhibitor) for Netherton syndrome entering clinic 2H 2024.","Avoralstat + Clearside SCS Microinjector for DME to enter clinic in 2025.","Oral C5 inhibitor for generalized myasthenia gravis to enter clinic in 2025.","Bifunctional complement inhibitor targeting multiple pathways for IgAN and lupus nephritis to enter clinic in 2025.","2024 R&D spending guided at $230-240M, up from projected 2023 spending of $25-35M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271968,"accession_number":"0001171843-23-006716","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst and Clearside partner to develop avoralstat for DME via SCS Microinjector; $5M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License agreement for avoralstat for diabetic macular edema using Clearside's SCS Microinjector.","BioCryst pays $5M upfront; Clearside eligible for up to $30M in clinical/regulatory milestones and up to $47.5M in sales milestones.","Avoralstat previously safe in Phase 3 HAE trial; high potency and low solubility suited for suprachoroidal delivery.","DME is common cause of vision loss; one-third of patients don't respond to anti-VEGF therapies.","BioCryst to host R&D Day today at 1:00 pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271967,"accession_number":"0001171843-23-006627","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q3 2023: ORLADEYO revenue $85.7M (+29.8% yoy); net loss narrows to $36.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 2023 revenue $86.7M (+14.4% yoy), driven by ORLADEYO growth of $19.7M.","Net loss $36.1M ($0.19/share) vs $42.5M ($0.23) in Q3 2022; operating cash use $16.5M (-43.9% yoy).","Full-year 2023 ORLADEYO revenue guidance reaffirmed at no less than $320M; peak revenue target $1B.","R&D expenses down 11% yoy to $46.9M due to program discontinuations; SG&A up 37% to $50.7M on ORLADEYO launch.","Cash and investments $399.2M at Sep 30, 2023; debt interest expense rose on Pharmakon facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":238011000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271966,"accession_number":"0001171843-23-006441","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst enrolls first patient in proof-of-concept trial for oral Factor D inhibitor BCX10013","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in open-label, multicenter dose-escalation trial of BCX10013 in up to 15 PNH patients.","Primary endpoints: treatment-emergent AEs, graded lab abnormalities; secondary: LDH, hemoglobin, transfusion-free rate.","If best-in-class profile confirmed in PNH, company plans to advance to pivotal program in renal complement diseases like IgAN.","Trial conducted in countries without standard-of-care complement inhibitor therapy; NCT06100900."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288821,"accession_number":"0001171843-23-004942","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).","GAAP net loss $75.3M ($0.40/share) vs $58.9M ($0.32/share) in Q2 2022; includes $29M one-time debt extinguishment fee.","Non-GAAP EPS ($0.24) after excluding the one-time fee; operating cash use $13.5M in Q2.","Reaffirmed FY 2023 ORLADEYO revenue guidance of >=$320M; peak revenue target $1B.","R&D day set for Nov 3, 2023 to introduce pipeline assets; BCX10013 trial enrollment in PNH expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":151269000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2317963520.3589134,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-03T23:59:59+00:00|288821"}